{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menopause/how-this-topic-was-developed/stakeholder-engagement/","result":{"pageContext":{"chapter":{"id":"4b187b70-dcd7-5e05-ac85-fd75204e2515","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement","depth":2,"htmlHeader":"<!-- begin field 0d40c585-cdae-4c6e-a937-a7f2017601b8 --><h2>Stakeholder engagement</h2><!-- end field 0d40c585-cdae-4c6e-a937-a7f2017601b8 -->","summary":null,"htmlStringContent":"<!-- begin item 4ea5ca5c-a87f-47d0-af1d-a7f20174d91e --><!-- begin field b6fdeba1-a7c1-4373-befa-a7f2017601b8 --><h2>Our policy</h2><!-- end field b6fdeba1-a7c1-4373-befa-a7f2017601b8 --><!-- begin field edfa6a5a-c6d1-4eda-b5e7-a7f2017601b8 --><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li>Clinical accuracy.</li><li>Consistency with other providers of clinical knowledge for primary care.</li><li>Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li>Usability.</li></ul><!-- end field edfa6a5a-c6d1-4eda-b5e7-a7f2017601b8 --><!-- begin field 0e3cf931-6792-4ef9-beeb-a7f2017601b8 --><h2>Principles of the consultation process</h2><!-- end field 0e3cf931-6792-4ef9-beeb-a7f2017601b8 --><!-- begin field d37541ea-5ba9-4852-8d1d-a7f2017601b8 --><ul><li>The process is inclusive and any individual may participate.</li><li>To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li>Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li>Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li>External reviewers are not paid for commenting on the draft topics.</li><li>Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li>All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li>All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><!-- end field d37541ea-5ba9-4852-8d1d-a7f2017601b8 --><!-- begin field 0a8da271-4f23-4910-979a-a7f2017601b8 --><h2>Stakeholders</h2><!-- end field 0a8da271-4f23-4910-979a-a7f2017601b8 --><!-- begin field 6231729e-7171-4e07-b5a8-a7f2017601b8 --><ul><li>Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href=\"http://cks.clarity.co.uk/get-involved/\" data-hyperlink-id=\"0bd10068-ec9d-4bfa-89a6-a93100cd6266\">Getting involved</a> section of the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"876b61eb-5a32-4b29-be33-a93100cd6305\">Clarity Informatics</a> website.</li><li>Stakeholders identified from the following groups are invited to review draft topics:<ul><li>Experts in the topic area.</li><li>Professional organizations and societies (for example, Royal Colleges).</li><li>Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li>Guideline development groups where the topic is an implementation of a guideline.</li><li>The British National Formulary team.</li><li>The editorial team that develop MeReC Publications.</li></ul></li><li>Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><!-- end field 6231729e-7171-4e07-b5a8-a7f2017601b8 --><!-- begin field c8ccb10c-8c67-426f-8145-a7f2017601b8 --><h2>Patient engagement</h2><!-- end field c8ccb10c-8c67-426f-8145-a7f2017601b8 --><!-- begin field 5da20043-08b6-403e-9e8d-a7f2017601b8 --><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li>Topic selection</li><li>Scoping of topic</li><li>Selection of clinical scenarios</li><li>First draft internal review</li><li>Second draft internal review</li><li>External review</li><li>Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p><!-- end field 5da20043-08b6-403e-9e8d-a7f2017601b8 --><!-- end item 4ea5ca5c-a87f-47d0-af1d-a7f20174d91e -->","topic":{"id":"69003588-b736-585d-8a5d-7ca0e916caa5","topicId":"f75fa6a7-10c6-4887-9cf1-3ea14d7f353c","topicName":"Menopause","slug":"menopause","lastRevised":"Last revised in November 2020","chapters":[{"id":"0359e5fa-1342-5767-a4da-2f8b5cd2b6db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c978ff88-dda8-5879-a0ac-9b09182d81d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d381eed9-6611-5263-a3be-b46ec9f02058","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ddcba55c-566e-5433-8dce-2e5f5cee0ba4","slug":"changes","fullItemName":"Changes"},{"id":"e521b2f5-34d4-580f-b63d-a1ec2d0c13a3","slug":"update","fullItemName":"Update"}]},{"id":"ab5690cf-81b4-5fa9-b69f-27abc2e034a3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0f45ff8-442c-5027-922e-12d108200960","slug":"goals","fullItemName":"Goals"},{"id":"8459ae09-bdf2-5d0d-9728-538e93d05a8f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"43027e52-84ef-53fa-88c5-a84289154e48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4620ee3c-97ae-5f9f-8bac-fc8497801cdb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b26fb3cf-562a-595a-8f9e-92fd752d2e6b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"10c1cb80-22cc-5889-8e30-35cf1a9843bf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18c173af-ec8a-571c-be49-d894f0bec50b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e86f5f5-2343-5ea3-8d0d-7dda791a066e","slug":"definition","fullItemName":"Definition"},{"id":"17295b39-3f33-5e75-8d8a-1fc32c2efb70","slug":"causes","fullItemName":"Causes"},{"id":"5b768dab-f7db-50c3-8686-0d363f36e74d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"698848d3-f122-5e5a-acc8-98518854f51b","slug":"complications","fullItemName":"Complications"},{"id":"647a928d-775d-5b0b-b577-b695140b26a3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00aeafb7-f9e4-5fd2-8fd2-57bd7fd333d8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d68ce2dd-2971-5c66-b22c-df0db848cf06","slug":"diagnosis-of-menopause-perimenopause","fullItemName":"Diagnosis of menopause and perimenopause"},{"id":"8b9c8208-91c2-5751-8a76-dc9461736050","slug":"diagnosis-of-premature-ovarian-insufficiency","fullItemName":"Diagnosis of premature ovarian insufficiency"},{"id":"a84016e1-b7af-55f9-b1f8-c85ff76cfc93","slug":"assessment","fullItemName":"Assessment"},{"id":"6c51a87c-f89c-5e58-b495-39506bc70e62","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"649507f8-7b95-5740-9833-fee7c5bff092","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c13d541-f2ee-5d0a-a174-cd7c7b4aa392","slug":"management-of-menopause-perimenopause-or-premature-ovarian-insufficiency","fullItemName":"Scenario: Management of menopause, perimenopause, or premature ovarian insufficiency"}]},{"id":"7d937659-3134-52f9-8742-b90a6ffb1f1f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"19b6008a-dd02-5fdb-b146-5cb427bb1f29","slug":"hormone-replacement-therapy-hrt","fullItemName":"Hormone replacement therapy (HRT)"}]},{"id":"ff6b5c36-2033-50a7-9c74-c9e46f1c8242","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c9280136-8c1b-5890-96e2-c8f14078bb5f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4f9c2c0d-8ea0-5048-8ae4-0b2517bed5ca","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b187b70-dcd7-5e05-ac85-fd75204e2515","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b3e44a7a-44e1-5dec-bd9e-67a0cad5baca","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e1b4175-c43f-53ce-8884-b9f1b5b39f58","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e0d3a8f-c4c1-533c-b265-34d08681175b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e6340cdd-13d8-5fde-912f-a3d2c50f305f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c9280136-8c1b-5890-96e2-c8f14078bb5f","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}